Close mobile menu×
Close mobile menu

Jennifer E. Amengual, MD

Board Certifications: 
Hematology, Medical Oncology, Internal Medicine
Expertise in: 
Lymphoma, Cancer Care
Accepting New Patients
Profile Headshot

Appointments

Phone Appointments

New and Existing Patients: 
(212) 326-5720

myColumbiaDoctors

For existing patients, login to make an appointment, view documentation or contact your care provider.

Credentials & Experience

Board Certifications

  • Hematology
  • Medical Oncology
  • Internal Medicine

Clinical Expertise

  • Lymphoma
  • Cancer Care
  • Leukemia
  • Bleeding Disorder
  • Coagulation Disorder
  • Anemia
  • Clinical Research
  • Clinical Research Trials

Education & Training

  • New York Medical College
  • Internship: Montefiore Medical Center
  • Residency: Montefiore Medical Center
  • Fellowship: New York University Medical Center

About Jennifer Amengual

Dr. Amengual is an Assistant Professor of Medicine and Developmental Therapeutics and a member of the Center for Lymphoid Malignancies here at Columbia University. Her research goals are focused on developing targeted therapies for the treatment of lymphoma. As a physician-scientist, she aims to directly translate observations and concepts developed in the laboratory to patient care.

Academic Titles

  • Assistant Professor of Medicine at CUMC

Hospital Affiliations

  • NewYork-Presbyterian/Columbia

Gender

  • Female

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Affinity

  • Essential Plan
  • Medicaid Managed Care
  • Medicare Managed Care

Amida Care

  • Special Needs Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • HMO
  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • Blue Priority
  • EPO
  • HMO
  • Medicare (Mediblue)
  • NYP Employee Plan
  • Pathway (Exchange)
  • POS
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Multiplan

  • Multiplan

Oxford Health Plans

  • Freedom
  • Liberty
  • Medicare Managed Care

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • EPO
  • Essential Plan
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

VNSNY CHOICE

  • Medicare Managed Care
  • SelectHealth

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

1
51 West 51st Street
Suite 200
New York, New York 10019
Phone:
(212) 326-5720
Fax:
(212) 326-5725
Primary

Research

Dr. Amengual is concentrated on targeting the Bcl-6 : p53 pathway in diffuse large B-cell lymphoma (DLBCL) with histone deacetylase (HDAC) inhibitors in order to shift the balance of oncogene and tumor suppressor to enforce a less neoplastic phenotype. She is evaluating novel combinations of pan-class HDAC inhibitors with class III sirtuin inhibitors in DLBCL cell lines for mechanism of action and cytotoxicity, novel in vivo mouse models for efficacy and tolerability, and evaluating pharmacokinetics and pharmacodynamic endpoints in a proof-of-principle phase I clinical trial. By exploiting rational targeted therapy to the discrete signaling pathways known to cause DLBCL, she hopes to increase cure rates for those with lymphoma.

Research Interests

  • Targeted therapies for the treatment of lymphoma

Grants

TAZEMETOSTAT ROLLOVER STUDY (TRUST): AN OPEN-LABEL, ROLLOVER STUDY (P&S Industry Clinical Trial)

Aug 27 2017 - Aug 27 2022

A PHASE IB/II, OPEN-LABEL, MULTICENTER STUDY OF THE SELECTIVE HDAC6 INHIBITOR, ACY-1215, FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY LYMPHOID MALIGNANCIES (P&S Industry Clinical Trial)

Mar 17 2014 - Mar 17 2019

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF THE BRUTON''S TYROSINE KINASE (BTK) INHIBITOR, PCI-32765 (IBRUTINIB), IN COMBINATION WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, AND PREDNISONE (R-CHOP) (P&S Industry Clinical Trial)

Jan 14 2014 - Jan 14 2019

A RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF A+AVD VERSUS ABVD AS FRONTLINE THERAPY IN PATIENTS WITH ADVANCED CLASSICAL HODGKIN LYMPHOMA (P&S Industry Clinical Trial)

Aug 16 2013 - Aug 16 2018

A RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED PHASE 3 STUDY OF THE BRUTON''S TYROSINE KINASE (BTK) INHIBITOR, PCI-32765 (IBRUTINIB), IN COMBINATION WITH BENDAMUSTINE AND RITUXIMAB (BR) IN SUBJECTS WITH NEWLY DIAGNOSED MANTLE CELL LYMPHOMA (P&S Industry Clinical Trial)

Jul 26 2013 - Jul 26 2018

TARGETING EPIGENETIC DERANGEMENTS IN GERMINAL CENTER-DERIVEDLYMPHOMAS THROUGH THE SYNERGISTIC DUAL INHIBITION OF EZH2 AND HISTONEDEACETYLASES (Private)

Jul 1 2017 - Jun 30 2018

A PHASE 2 SINGLE-ARM, OPEN-LABEL STUDY OF SINGLE-AGENT BRENTUXIMAB VEDOTIN FOR FRONT-LINE THERAPY OF HODGKIN (P&S Industry Clinical Trial)

Feb 25 2013 - Feb 25 2018

A STUDY OF THE PHARMACOLOGIC ACTIVITY OF HE HAT ACTIVATORS IN MODELS OF LYMPHOMA (Private)

Nov 6 2015 - Jul 31 2017

A STUDY OF THE PHARMACOLOGIC ACTIVITY OF BTK AND IRAK4 INHIBITORS IN MODELS OF LYMPHOMA (Private)

Dec 17 2015 - Dec 16 2016

IDENTIFYING PATTERNS OF MUTATIONS IN EPIGENETIC MODIFIES AS A STRATEGY TO DIRECT TARGETING OF THE TRANSCRIPTIONALLY REPRESSED SLATE OF GERMINAL-CENTER DERIVED LYMPHOMAS (Private)

Oct 1 2015 - Sep 30 2016

EPIGENTIC MODULATION OF THE BC16: P53 AXIS IN AGGRESSIVE LYMPHOMAS (Private)

Jul 1 2012 - Jun 30 2016

A STUDY OF THE PHARMACOLOGIC ACTIVITY OF THE HDAC6 INHIBITOR ACY1215 IN MODELS OF LYMPHOMA (Private)

Mar 20 2014 - Mar 19 2016

DEVELOPMENT AND CHARACTERIZATION OF AN HDAC6 INHIBITOR DLBCL CELL LINE (Private)

Jun 1 2014 - Sep 30 2014

THERAPEUTIC TARGETING OF THE BCL6: P53 AXIS WITH HITONE DEACTYLASE INHIBITORS IN DIFFUSE LARGE B-CELL LYMPHOMA (Private)

Mar 1 2012 - Feb 28 2014

LLS TRANSLATIONAL RESEARCH PROGRAM (Private)

Jan 1 2012 - Sep 30 2013

A STUDY OF THE PHARMACOLOGIC ACTIVITY OF THE HDAC6 INHIBITOR ACY 1215 IN MODELS OF LYMPHOMA (Private)

Apr 26 2012 - Mar 1 2013